Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

1.

Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature.

Papadimitriou K, Kountourakis P, Morakis E, Vassiliou V, Barbounis V, Ardavanis A.

Case Rep Med. 2012;2012:810428. doi: 10.1155/2012/810428. Epub 2012 Apr 11.

PMID:
22567020
[PubMed]
Free PMC Article
2.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
[PubMed - indexed for MEDLINE]
3.

Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?

Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.

Clin Breast Cancer. 2009 Feb;9(1):34-8. doi: 10.3816/CBC.2009.n.006.

PMID:
19299238
[PubMed - indexed for MEDLINE]
4.
5.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
[PubMed - indexed for MEDLINE]
6.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.

PMID:
22265698
[PubMed - indexed for MEDLINE]
7.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
8.

Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.

Berry J.

Clin Ther. 2005 Nov;27(11):1671-84. Review.

PMID:
16368441
[PubMed - indexed for MEDLINE]
9.

Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.

Moegele M, Buchholz S, Seitz S, Ortmann O.

Arch Gynecol Obstet. 2012 May;285(5):1397-402. doi: 10.1007/s00404-011-2181-6. Epub 2012 Jan 3. Review.

PMID:
22212649
[PubMed - indexed for MEDLINE]
10.

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.

Conte P, Frassoldati A.

Breast J. 2007 Jan-Feb;13(1):28-35. Review.

PMID:
17214790
[PubMed - indexed for MEDLINE]
11.

Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.

Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C.

Breast Cancer Res Treat. 2010 Feb;120(1):127-34. doi: 10.1007/s10549-009-0692-7. Epub 2009 Dec 25.

PMID:
20035381
[PubMed - indexed for MEDLINE]
12.

Exemestane: a review of its use in postmenopausal women with breast cancer.

Deeks ED, Scott LJ.

Drugs. 2009;69(7):889-918. doi: 10.2165/00003495-200969070-00007. Review.

PMID:
19441873
[PubMed - indexed for MEDLINE]
13.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

PMID:
17610808
[PubMed - indexed for MEDLINE]
Free Article
14.

Aromatase inhibitor-associated arthralgia syndrome.

Burstein HJ.

Breast. 2007 Jun;16(3):223-34. Epub 2007 Mar 21. Review.

PMID:
17368903
[PubMed - indexed for MEDLINE]
15.

The role of aromatase inhibitors in the treatment of metastatic breast cancer.

Mouridsen H, Gershanovich M.

Semin Oncol. 2003 Aug;30(4 Suppl 14):33-45. Review.

PMID:
14513435
[PubMed - indexed for MEDLINE]
16.

Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.

Younus M, Kissner M, Reich L, Wallis N.

Drug Saf. 2011 Dec 1;34(12):1125-49. doi: 10.2165/11594170-000000000-00000. Review.

PMID:
22077502
[PubMed - indexed for MEDLINE]
17.

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.

PMID:
17919537
[PubMed - indexed for MEDLINE]
18.

Role of aromatase inhibitors in the treatment of breast cancer.

Choueiri TK, Alemany CA, Abou-Jawde RM, Budd GT.

Clin Ther. 2004 Aug;26(8):1199-214. Review.

PMID:
15476902
[PubMed - indexed for MEDLINE]
19.

Molecular Action and Clinical Relevance of Aromatase Inhibitors.

Murphy MJ Jr.

Oncologist. 1998;3(2):129-130.

PMID:
10388095
[PubMed - as supplied by publisher]
Free Article
20.

Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.

Henry NL, Giles JT, Stearns V.

Oncology (Williston Park). 2008 Nov 15;22(12):1401-8. Review.

PMID:
19086600
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk